Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) primary prophylaxis in patients undergoing hematopoietic stem cell transplantation: a network meta-analysis of randomized clinical trials

Author:

Sousa-Pimenta Mário1,Martins Ângelo1,Vaz Carlos Pinho1,Leite Luís1,Mariz José1

Affiliation:

1. Department of Hematology and Bone Marrow Transplantation, Portuguese Oncology Institute of Porto (IPO-Porto)

Abstract

Abstract Introduction: Hepatic sinusoidal obstruction/veno-occlusive syndrome (SOS/VOD) is a major complication following hematopoietic stem cell transplantation, resulting from immune and chemical toxicity to the sinusoidal endothelium and hepatocellular damage. In most severe cases, multiorgan dysfunction occurs, so it is essential to promptly identify patients at greater risk of SOS/VOD and to adopt prophylactic strategies. Objectives This study aims to systematize the impact of different approaches as primary prophylaxis of SOS/VOD in patients undergoing hematopoietic progenitors stem cell transplantation (HSCT). Methods A systematic review and meta-analysis of randomized clinical trials evaluating different strategies for primary prophylaxis of SOS/VOD was carried out in a pairwise fashion and with a consistent network structure. The odds ratio (OR) and corresponding confidence intervals were calculated using the random-effects model. Heterogeneity was assessed by the I2 method and the efficacy of each approach was estimated by SUCRA (surface under the cumulative ranking curve). Results Considering all patients undergoing HSCT, ursodeoxycholic acid (UDCA) [OR = 0.38, 95%CI 0.14–1.06, SUCRA = 0.720] was associated with a lower incidence of VOD while defibrotide reached a modest reduction in its incidence [OR = 0.64, 95%CI 0.23–1.67; SUCRA = 0.486]. Considering the subgroup of patients undergoing hematopoietic progenitors allotransplantation, defibrotide scored higher [OR = 0.51, 95%CI 0.09–2.85, SUCRA = 0.650], by comparison with UDCA [OR = 0.53, 95%CI 0.14–1.96, SUCRA = 0.639]. Conclusion This is the first meta-analysis comparing primary prophylaxis of SOS/VOD. UDCA yielded more promising results when considering all patients undergoing hematopoietic stem cell transplantation, although, in a subgroup analysis of the ones exposed to allogeneic grafts, it becomes not significantly overrun by defibrotide.

Publisher

Research Square Platform LLC

Reference40 articles.

1. Carreras E, Bertz H, Arcese W, Vernant J-P, Tomás J-F, Hagglund H et al (1998) Incidence and Outcome of Hepatic Veno-Occlusive Disease After Blood or Marrow Transplantation: A Prospective Cohort Study of the European Group for Blood and Marrow Transplantation. Blood [Internet]. ;92(10):3599–604. https://doi.org/10.1182/blood.V92.10.3599

2. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients;Barker CC;Bone Marrow Transplant,2003

3. The role of the endothelium in the short-term complications of hematopoietic SCT;Carreras E;Bone Marrow Transplant,2011

4. Richardson PG, Ho VT, Cutler C, Glotzbecker B, Antin JH, Soiffer R (2013) Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Novel Insights to Pathogenesis, Current Status of Treatment, and Future Directions. Biol Blood Marrow Transplant [Internet]. ;19(1, Supplement):S88–90. Available from: https://www.sciencedirect.com/science/article/pii/S1083879112004521

5. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation;Bonifazi F;Front Immunol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3